MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verve Therapeutics
VERV
|
+$20.3M |
| 2 |
Regenxbio
RGNX
|
+$18.4M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$13.8M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$5.77M |
| 5 |
Intellia Therapeutics
NTLA
|
+$4.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EPZM
Epizyme, Inc
EPZM
|
+$5.04M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
+$4.6M |
| 3 |
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$2.53M |
| 4 |
Amicus Therapeutics
FOLD
|
+$1.14M |
| 5 |
NeoGenomics
NEO
|
+$1.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$737M
| $98.1M | 23.22% |
7,648,268
| – | – |
2021 Q1
6 quarters
|
|
2
DELISTED
iTeos Therapeutics
ITOS
| $33.3M | 7.88% |
1,745,943
| – | – |
2020 Q3
8 quarters
|
|
3
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $23M | 5.44% |
1,279,995
+256,670
| +25% | +$4.63M |
2022 Q2
1 quarter
|
|
|
4
DELISTED
Verve Therapeutics
VERV
| $21.8M | 5.17% |
+635,792
| New | +$20.3M |
2022 Q3
0 quarters
|
|
|
5
Intellia Therapeutics
NTLA
$1.6B
| $21M | 4.96% |
374,409
+75,000
| +25% | +$4.65M |
2021 Q3
4 quarters
|
|
6
DELISTED
Repare Therapeutics
RPTX
| $19.9M | 4.71% |
1,639,849
| – | – |
2020 Q2
9 quarters
|
|
7
Geron
GERN
$657M
| $19.7M | 4.67% |
8,422,582
-12,409
| -0.1% | -$27.8K |
2021 Q3
4 quarters
|
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $18.8M | 4.46% |
+1,050,000
| New | +$13.8M |
2022 Q3
0 quarters
|
|
9
DELISTED
Merus
MRUS
| $18.4M | 4.36% |
918,310
-1,172
| -0.1% | -$28K |
2020 Q2
9 quarters
|
|
|
10
Regenxbio
RGNX
$560M
| $16.4M | 3.88% |
+619,083
| New | +$18.4M |
2022 Q3
0 quarters
|
|
|
11
Iovance Biotherapeutics
IOVA
$3.74B
| $16.3M | 3.86% |
1,700,000
+500,000
| +42% | +$5.77M |
2022 Q2
1 quarter
|
|
12
Werewolf Therapeutics
HOWL
$48.1M
| $10.8M | 2.55% |
2,388,011
| – | – |
2021 Q2
5 quarters
|
|
13
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $10.7M | 2.53% |
856,798
| – | – |
2019 Q4
11 quarters
|
|
14
Cytokinetics
CYTK
$8.15B
| $9.36M | 2.22% |
193,205
-1,041
| -0.5% | -$50.1K |
2021 Q3
4 quarters
|
|
15
BioCryst Pharmaceuticals
BCRX
$1.97B
| $7.63M | 1.81% |
605,663
-33,426
| -5% | -$430K |
2021 Q3
4 quarters
|
|
16
DELISTED
Crinetics Pharmaceuticals
CRNX
| $7.16M | 1.7% |
364,710
-1,966
| -0.5% | -$40.1K |
2021 Q3
4 quarters
|
|
17
Travere Therapeutics
TVTX
$5B
| $6.81M | 1.61% |
276,460
-1,490
| -0.5% | -$38.5K |
2021 Q3
4 quarters
|
|
18
DELISTED
Y-mAbs Therapeutics
YMAB
| $6.4M | 1.52% |
443,702
| – | – |
2019 Q4
11 quarters
|
|
|
TCRR
19
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $6.07M | 1.44% |
3,370,982
| – | – |
2019 Q4
11 quarters
|
|
20
Harmony Biosciences
HRMY
$2.01B
| $6.06M | 1.43% |
136,780
-737
| -0.5% | -$36K |
2021 Q3
4 quarters
|
|
21
Arcutis Biotherapeutics
ARQT
$3.59B
| $4.92M | 1.16% |
257,185
-1,315
| -0.5% | -$29.8K |
2022 Q1
2 quarters
|
|
|
RETA
22
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $4.5M | 1.07% |
179,058
-942
| -0.5% | -$26.1K |
2022 Q1
2 quarters
|
|
|
23
DELISTED
Amicus Therapeutics
FOLD
| $4.1M | 0.97% |
392,946
-102,657
| -21% | -$1.14M |
2021 Q3
4 quarters
|
|
|
PRVB
24
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $3.33M | 0.79% |
740,344
+147,909
| +25% | +$674K |
2022 Q2
1 quarter
|
|
|
HARP
25
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $3.1M | 0.73% |
319,671
| – | – |
2019 Q4
11 quarters
|
|
Similar funds
MPM BioImpact's Q3 2022 Portfolio in Review
As of Q3 2022, MPM BioImpact held 41 positions worth $422M, up 17% from $360M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
MPM BioImpact deployed $55.4M of net new capital in Q3 2022, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Verve Therapeutics: 635,792 shares worth $21.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Mirum Pharmaceuticals, an estimated $4.6M trimmed.
- MPM BioImpact's largest Q3 2022 buy was Verve Therapeutics: 635,792 shares worth $21.8M.
- MPM BioImpact added most to Iovance Biotherapeutics in Q3 2022, an estimated $5.77M increase.
- MPM BioImpact's biggest Q3 2022 reduction was Mirum Pharmaceuticals, cutting an estimated $4.6M.
- MPM BioImpact fully exited Epizyme, Inc in Q3 2022, selling an estimated $5.04M.
- MPM BioImpact's ten largest holdings make up 69% of its $422M portfolio in Q3 2022.
- MPM BioImpact opened 4 new positions and closed 3 in Q3 2022.
- MPM BioImpact's portfolio value rose 17% quarter-over-quarter to $422M.
Based on MPM BioImpact's 13F filing for Q3 2022, filed 14 Nov 2022.